Lataa...
Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus
The efficacy and safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, as monotherapy have been widely confirmed in a large body of clinical studies of up to 2 years’ duration in various populations with type 2 diabetes mellitus. This paper reviews the data supporting the use of vildagliptin...
Tallennettuna:
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2012
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3363148/ https://ncbi.nlm.nih.gov/pubmed/22661900 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/VHRM.S31758 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|